A Plasma MicroRNA Panel for Detection of Colorectal Adenomas

• DOI: 10.1097/sla.0b013e3182a15bcc
• Publication Date: 2013-08-09T11:23:27Z
• Authors: Ziad Kanaan; Henry Roberts; M. Robert Eichenb...; Adrian Billeter; Gairy Ocheretner; Jianmin Pan; Shesh N. Rai; Jeffery Jorden; Anna Williford; Susan Galandiuk
• Keywords: Colorectal adenoma

In Brief Objective: The main objective of this study was to investigate the potential use circulating microRNAs (miRNAs) as biomarkers colorectal (CR) adenomas. Background: Detection precancerous lesions such CR adenoma is a key reduce cancer (CRC) mortality. There great need for accurate, noninvasive detection and CRC. MiRNAs are non-protein-coding RNAs that regulate gene expression. Our prior work investigated dysregulation 5 plasma miRNAs in CRC patients. As intended, we undertook more comprehensive plasma-miRNA screening patients with Methods: We screened 380 plasma-miRNAs using microfluidic array technology (Applied BioSystems) cohort 12 healthy controls, 9 adenomas, 20 A panel most dysregulated (P < 0.05, False Discovery Rate: 5%) then validated blinded 26 16 large 45 Results: 8 (miR-532-3p, miR-331, miR-195, miR-17, miR-142-3p, miR-15b, miR-532, miR-652) distinguished polyps from controls high accuracy [area under curve (AUC) = 0.868 (95% confidence interval [CI]: 0.76–0.98)]. addition, 3 (miR-431, miR-139-3p) Stage IV an [AUC 0.896 CI: 0.78–1.0)]. Receiver-operating-characteristic curves miRNA panels all versus showed AUC values 0.829 0.73–0.93) 0.856 0.75–0.97), respectively. Conclusions: Plasma reliable, noninvasive, inexpensive markers This warrants larger cohorts. Plasma-based assays could provide better compliance compared fecal occult blood or endoscopic screening. MicroRNAs were initially adenomas both groups, evaluated training sets test sets. proved be sensitive specific patient cohort.